AdvaMed’s six recommendations are:
- · Make innovation in life sciences a priority.
- · Reform the FDA review process.
- · Establish payment policies that support innovation.
- · Change trade policies to provide a level playing field for domestic manufacturing.
- · Implement tax policies that are fair to the device industry.
- · Sustain and improve U.S. research and development.
“We know medical technology has a bright future,” said Stephen Ubl, president and CEO of AdvaMed, in the release. “The question is: Will that future be made in America—or somewhere else?”
Read the AdvaMed release on medical devices.
Related Articles on AdvaMed:
Study: No Safety Benefit Recognized From Slower, Burdensome FDA Approval Process for Devices
Medical Device Group Lobbies Congress on Patient Lawsuits, FDA Approval System
